Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Cash from Financing Activities (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Cash from Financing Activities data on record, last reported at $581000.0 in Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 14425.0% year-over-year to $581000.0; the TTM value through Dec 2025 reached $1.0 million, down 99.03%, while the annual FY2025 figure was $1.0 million, 99.03% down from the prior year.
  • Cash from Financing Activities reached $581000.0 in Q4 2025 per FHTX's latest filing, up from $49000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $103.2 million in Q2 2024 and bottomed at $4000.0 in Q4 2024.
  • Average Cash from Financing Activities over 5 years is $6.6 million, with a median of $293500.0 recorded in 2022.
  • Peak YoY movement for Cash from Financing Activities: tumbled 99.93% in 2022, then soared 100100.0% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $21.7 million in 2021, then crashed by 99.93% to $16000.0 in 2022, then skyrocketed by 1062.5% to $186000.0 in 2023, then plummeted by 97.85% to $4000.0 in 2024, then soared by 14425.0% to $581000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $581000.0 in Q4 2025, $49000.0 in Q3 2025, and $254000.0 in Q2 2025.